Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer

A. E. C. A. B. Willemsen, L. M. Knapen, Y. M. de Beer, R. J. M. Bruggemann, S. Croes, C. M. L. van Herpen, N. P. van Erp

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)465-471
Number of pages7
JournalEuropean Journal of Clinical Pharmacology
Volume74
Issue number4
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • Cancer
  • Everolimus
  • Dried blood spot
  • Pharmacokinetics
  • Therapeutic drug monitoring
  • Method agreement
  • TANDEM MASS-SPECTROMETRY
  • RENAL-CELL CARCINOMA
  • NEUROENDOCRINE TUMORS
  • CYCLOSPORINE-A
  • PHASE-I
  • HEMATOCRIT
  • PHARMACOKINETICS
  • PERFORMANCE
  • TACROLIMUS
  • EXPOSURE
  • Predictive Value of Tests
  • Antineoplastic Agents/administration & dosage
  • Dried Blood Spot Testing
  • Humans
  • Middle Aged
  • Male
  • Tandem Mass Spectrometry
  • Drug Dosage Calculations
  • Chromatography, Liquid
  • Adult
  • Female
  • Reproducibility of Results
  • Drug Monitoring/methods
  • Aged
  • Everolimus/administration & dosage
  • Neoplasms/blood

Cite this